A 412-patient trial comparing 3 dosing regimens of abelacimab versus enoxaparin, results indicate all 3 regimens of abelacimab demonstrated noninferiority against enoxaparin and 2 of the 3 demonstrated superiority against the current standard of care.
Simultaneously published in JAMA, the PER DIEM and STROKE-AF trials demonstrate the ability of Medtronic's insertable cardiac monitor, Reveal LlNQ, to improve detection of atrial fibrillation in patients with a history of stroke.
The American Heart Association and American Stroke Association have released an updated version of their guidelines for prevention of secondary stroke in patients with stroke or TIA, which had not been updated since 2014.
Results of the LAAOS III trial provide evidence suggesting left atrial appendage occlusion could reduce risk of ischemic events by nearly a third and also reduce risk of stroke by more than 40% in patients with atrial fibrillation.
Dr. Gregory Weiss, a cardiovascular anesthesiologist, breaks down and provides real-world perspective on the application of a recent scientific statement from the AHA and ASA on perioperative management to lower stroke risk in patients undergoing noncardiac and nonneurological procedures.
An analysis of claims data by investigators at University of Pennsylvania indicates DOACs were associated with a 36% lower risk of stroke or systemic embolism and was also associated with a reduction in risk of major bleeding.
Check out this interview with Louise McCullough, MD, PhD, Program Chair of ISC 21, where she offers perspective on mobile stroke units and what barriers prevent further implementation of the specialized ambulatory units.
Just ahead of the International Stroke Conference, the AHA released a scientific statement focusing on brain health and aimed at providing primary care providers an overview of factors influencing neurologic health.